title: Height and mortality after myocardial infarction.
abstract: A case-control analysis was conducted to determine the relationship between height and mortality among patients enrolled in the already completed Beta Blocker Heart Attack Trial (BHAT). In a basic model including height (continuous) and relevant covariates the relative risk (RR) per 4-inch reduction in height (approximately 1 standard deviation) was 1.18 (95% confidence interval, 0.92 to 1.51). When sex was considered, the effect of short stature on mortality was found to be restricted to male subjects. The male RR per 4-inch reduction in height was 1.26 (0.96 to 1.63) whereas for women it was 0.89 (0.49 to 1.59). In males not randomized to propranolol (untreated) the effect was further modified with a RR per 4-inch reduction in height of 1.41 (1.00 to 1.99). It is hypothesized that short stature could be a marker for factors operating as far back as childhood that predispose males to mortality from coronary heart disease in later life.
authors.affiliation: IPRO, Lake Success, NY 11042, USA.
authors.forename: C R
authors.initials: CR
authors.lastname: Rosenberg
authors.forename: R E
authors.initials: RE
authors.lastname: Shore
authors.forename: B S
authors.initials: BS
authors.lastname: Pasternack
mesh_terms: D000328:Adult; D000368:Aged; D001827:Body Height / Q000502:physiology*; D016022:Case-Control Studies; D002423:Cause of Death; D016001:Confidence Intervals; D004311:Double-Blind Method; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality*; D011433:Propranolol / Q000627:therapeutic use; D016019:Survival Analysis
chemical_list: D011433:Propranolol